Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2, has spread globally, and no proven treatments are available. Convalescent plasma …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2, has spread globally, and proven treatments are limited. Transfusion of …

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We …

Coronavirus disease 2019 (COVID-19) convalescent plasma has emerged as a promising
therapy and has been granted Emergency Use Authorization by the US Food and Drug …

Newly emerged pathogens such as SARS-CoV-2 highlight the urgent need for assays that
detect levels of neutralizing antibodies that may be protective. We studied the relationship …

Background COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has spread globally, and no proven treatments are available. Convalescent …

Millions of individuals who have recovered from SARS-CoV-2 infection may be eligible to
participate in convalescent plasma donor programs, yet the optimal window for donating high …

BACKGROUND Antibodies to Rhesus and Kell antigens have been associated with severe
hemolytic disease of the fetus and newborn (HDFN) necessitating intrauterine transfusion (…

The use of percutaneous ventricular assist devices (VADs) in the acute management of
cardiogenic shock is becoming increasingly common. The Impella is a percutaneous VAD, which …

Background Apheresis procedures require adequate vascular access to achieve adequate
inlet flow rates. Central dialysis‐type catheters are often used in apheresis, despite their …